Can Novartis Reclaim Pioneering Role In Transplantation?
An Interview With Eric Hughes, Head Of Immunology, Hepatology and Dermatology At Novartis
Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reducing the pressure on transplant waiting lists and improving the long-term outlook for patients.
